The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $10 from $18 and keeps an Outperform rating on the shares. The firm ...

Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.

Editas Medicine and Genevant Sciences will collaborate to develop gene editing therapies, employing their respective CRISPR ...

Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sci ...

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid ...